V116 + Pneumovax™23
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia, Pneumococcal
Conditions
Pneumonia, Pneumococcal
Trial Timeline
Dec 6, 2019 → Jul 12, 2021
NCT ID
NCT04168190About V116 + Pneumovax™23
V116 + Pneumovax™23 is a phase 1/2 stage product being developed by Merck for Pneumonia, Pneumococcal. The current trial status is completed. This product is registered under clinical trial identifier NCT04168190. Target conditions include Pneumonia, Pneumococcal.
What happened to similar drugs?
20 of 20 similar drugs in Pneumonia, Pneumococcal were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04665050 | Phase 1 | Completed |
| NCT04168190 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pneumonia, Pneumococcal